HYCOS: A NOVEL CLASS OF ANTI-INFLAMMATORY AGENTS

ERGANEO



18 Avril 2016

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

Heme oxygenase-1 (HO-1), an inducible enzyme that degrades heme to carbon monoxide (CO) and which expression is controlled by the transcription factor Nrf2, is an essential protective system against oxidative stress and inflammation. Developing strategies that target or mimic the Nrf2/HO-1/CO axis may offer new therapeutic avenues in the treatment of a variety of diseases. Our technology consists of a novel class of anti-inflammatory hybrid compounds termed HYCOs that are able to activate Nrf2/HO-1 and simultaneously liberate CO in vitro and in vivo. HYCOs have shown significant anti-inflammatory effects in different cell types (macrophages, monocytes, keratinocytes, microglia) and efficacy in pre-clinical models of psoriasis, endotoxin-induced inflammation as well as multiple sclerosis.

Competitive advantages:

  • Novel class of anti-inflammatory chemical entities
  • Novel therapeutic approach with a dual biological activity
  • Comparable efficacy with DMF, an orally approved drug for the treatment of multiple sclerosis


Applications:

  • Treatment of inflammatory diseases, multiple sclerosis, psoriasis
  • Cardiovascular protection


Keywords:

Nrf2, CO-releasing molecules (CO-RMs), Small molecules, Anti-inflammatory, Cardiovascular, Psoriasis, Multiple Sclerosis

Download the offer Download the offer

Newsletter